Pradžia › Pjautinio ląstelės anemija › Alabama
Pjautinio ląstelės anemija klinikiniai tyrimai Alabama
16 tyrimai dėl Pjautinio ląstelės anemija ieško dalyvių vietose Alabama.
Miestai Alabama
Oficialus tyrimo tekstas (anglų kalba)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- University Of Alabama, Birmingham
Renkami dalyviai3 fazė
Amžius nuo 12 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Uni of Alabama at Birmingham, Birmingham
- Univer South Alabama Ped/Onc, Mobile
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06612268A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- University of Alabama Birmingham, Birmingham
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Amžius nuo 12 iki 55 · Visoms lytims · Atnaujinta 2026-09-09 · NCT06546670SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06442761A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- AMR Clinical, Mobile
Renkami dalyviai2/3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT05431088The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
Renkami dalyviai3 fazė
Amžius nuo 10 iki 65 · Visoms lytims · Atnaujinta 2026-07-29 · NCT06975865Early Life Exposures Among Children With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai
Amžius nuo 18 iki 50 · Moterims · Atnaujinta 2026-07-15 · NCT05377372Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- University Of Alabama, Birmingham
Renkami dalyviai4 fazė
6 Months – 100 Years · Visoms lytims · Atnaujinta 2026-06-08 · NCT04657822Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 3 iki 20 · Visoms lytims · Atnaujinta 2026-06-04 · NCT06941389Cognitive Remediation Intervention to Prepare for Transition of Care
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai2 fazė
Amžius nuo 10 iki 18 · Visoms lytims · Atnaujinta 2026-02-27 · NCT05336201A Long-term Follow-up Study in Patients Who Received BEAM-101
- University of Alabama at Birmingham, Birmingham
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 14 iki 37 · Visoms lytims · Atnaujinta 2026-01-28 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- University of South Alabama Medical Center, Mobile
Renkami dalyviai
Amžius nuo 16 iki 30 · Visoms lytims · Atnaujinta 2026-01-07 · NCT06374238HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 12 iki 80 · Visoms lytims · Atnaujinta 2025-08-28 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Alabama, Birmingham (UAB), Birmingham
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-06-22 · NCT06385886Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.